Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage (Seite 2285)
eröffnet am 25.04.09 09:22:26 von
neuester Beitrag 15.06.24 06:30:32 von
neuester Beitrag 15.06.24 06:30:32 von
Beiträge: 23.722
ID: 1.149.910
ID: 1.149.910
Aufrufe heute: 233
Gesamt: 1.281.649
Gesamt: 1.281.649
Aktive User: 0
ISIN: US6700024010 · WKN: A2PKMZ · Symbol: NVV1
13,446
EUR
-4,08 %
-0,572 EUR
Letzter Kurs 14.06.24 Tradegate
Neuigkeiten
| TitelBeiträge |
|---|
13.06.24 · Felix Haupt Anzeige |
07.06.24 · LYNX Analysen Anzeige |
23.05.24 · wallstreetONLINE Redaktion |
Shortseller bluten: Novavax: Aktie steigt um weitere 50 Prozent – Sanofi-Deal leitet Turnaround ein! 14.05.24 · wallstreetONLINE Redaktion |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8000 | +2.566,67 | |
| 3,3000 | +44,74 | |
| 1,2200 | +31,76 | |
| 1,2450 | +29,69 | |
| 7,7600 | +29,33 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,7900 | -24,80 | |
| 1,0100 | -26,81 | |
| 9,5300 | -34,00 | |
| 1,0200 | -34,19 | |
| 1,2400 | -34,39 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 37.894.019 von sharp2008 am 01.09.09 15:31:44was meint ihr in welcher schweinegrippeaktie am meisten potenzial ist bei ntv wird von einer 1000% aktie gesprochen?
SINOVAC
SINOVAC
NEWS: 3 Personen angeblich mit H1N1 UND H5N1 Virus infiziert !
Wenn das wirklich zutreffen sollte , wirds jetzt gefährlich !
Co-transmission of H5N1 with Pandemic H1N1 in Egypt? Recombinomics Commentary 18:16
September 2, 2009
A 35 year-old Italian tourist is one of three people believed to have been infected with A(H1N1) virus, or swine flu, as well as the H5N1 virus, known as avian flu. The patients are recovering in the Egyptian Red Sea resort of Hurghada, said Mohammed Rifai, director general of preventive medicine.
Rifai also spoke of a 28-year-old man who tested positive for both viruses, after arriving at the port of Safaga after a pilgrimage to Saudi Arabia.
"We are waiting the results of the tests that have already been carried out in some patients suspected of having been infected by the H5N1 and the A(H1N1)," said World Health Organisation spokesman Gregory Hartl in an interview with Adnkronos Salute.
The above comments raise concerns of co-infections of pandemic H1N1 and H5N1, as well as human to human co-transmission. This development would create serious pandemic concerns.
The ability of the pandemic H1N1 to infected multiple species has been demonstrated by the widespread outbreaks in swine. Outbreaks in Canada have been reported in three provinces (Alberta, Quebec, and Manitoba) as well as two locations in Argentina near Buenos Aires, as well as three locations in Australia, These swine infections demonstrate the ease of transmission from humans to swine, as well as swine to swine. Recent results in Chile also demonstrated transmission to turkeys, raising concerns that H1N1 could be silently transmitting to multiple mammalian and avian species.
The jump to avian raised concerns that the H1N1 could interact with H5N1, which is predominantly found in birds, including long range migratory birds. Recent data also demonstrated H5N1 in pikas at Qinghai Lake, which is a mammalian reservoir.
Results from Egypt also raised concerns of co-infections because of the large number of mild H5N1 cases and the concentration in children. The heavy concentration in children raised concerns of silent spread of H5N1 in adults, providing opportunities for co-infection, which could lead to the H1N1 "rescuing" H5N1 leading to co-transmissions.
The presence of both viruses in multiple individuals identified over a brief time period suggests the viruses are efficiently co-transmitting, which creates serious concerns due to co-infections, or exchanges of genetic information via reassortment or recombination. Mammalian polymorphisms have been noted in prior H5N1 isolates, and pandemic H1N1 has H5N1 polymorphisms, indicating exchanges via recombination have happened previously.
However- co-infection and co-transmission would significantly increase the frequency and efficiency of recombination, which would be serious cause for concerns.
Confirmation that these three patients have co-infections of H5N1 and H1N1 (or swine and seasonal H1N1) would be useful
-----------------------------------------
Sollte der Virus sich verbreiten muß ein NEUER Impfstoff dafür entwickelt werden, dann sind in der Zwischzeit Relanza oder Tamiflu die letzte Bastion die Krankeit zu behandeln !
Aktientechnisch gilt dann eher der Blick auf die antiviralen Grippemittel,
bzw. den Aktien Biota (Relenza + Laninamivir), Glaxo , Roche, Gilead (Tamiflu), Biocryst (Peramivir)
gruß
massel
Wenn das wirklich zutreffen sollte , wirds jetzt gefährlich !
Co-transmission of H5N1 with Pandemic H1N1 in Egypt? Recombinomics Commentary 18:16
September 2, 2009
A 35 year-old Italian tourist is one of three people believed to have been infected with A(H1N1) virus, or swine flu, as well as the H5N1 virus, known as avian flu. The patients are recovering in the Egyptian Red Sea resort of Hurghada, said Mohammed Rifai, director general of preventive medicine.
Rifai also spoke of a 28-year-old man who tested positive for both viruses, after arriving at the port of Safaga after a pilgrimage to Saudi Arabia.
"We are waiting the results of the tests that have already been carried out in some patients suspected of having been infected by the H5N1 and the A(H1N1)," said World Health Organisation spokesman Gregory Hartl in an interview with Adnkronos Salute.
The above comments raise concerns of co-infections of pandemic H1N1 and H5N1, as well as human to human co-transmission. This development would create serious pandemic concerns.
The ability of the pandemic H1N1 to infected multiple species has been demonstrated by the widespread outbreaks in swine. Outbreaks in Canada have been reported in three provinces (Alberta, Quebec, and Manitoba) as well as two locations in Argentina near Buenos Aires, as well as three locations in Australia, These swine infections demonstrate the ease of transmission from humans to swine, as well as swine to swine. Recent results in Chile also demonstrated transmission to turkeys, raising concerns that H1N1 could be silently transmitting to multiple mammalian and avian species.
The jump to avian raised concerns that the H1N1 could interact with H5N1, which is predominantly found in birds, including long range migratory birds. Recent data also demonstrated H5N1 in pikas at Qinghai Lake, which is a mammalian reservoir.
Results from Egypt also raised concerns of co-infections because of the large number of mild H5N1 cases and the concentration in children. The heavy concentration in children raised concerns of silent spread of H5N1 in adults, providing opportunities for co-infection, which could lead to the H1N1 "rescuing" H5N1 leading to co-transmissions.
The presence of both viruses in multiple individuals identified over a brief time period suggests the viruses are efficiently co-transmitting, which creates serious concerns due to co-infections, or exchanges of genetic information via reassortment or recombination. Mammalian polymorphisms have been noted in prior H5N1 isolates, and pandemic H1N1 has H5N1 polymorphisms, indicating exchanges via recombination have happened previously.
However- co-infection and co-transmission would significantly increase the frequency and efficiency of recombination, which would be serious cause for concerns.
Confirmation that these three patients have co-infections of H5N1 and H1N1 (or swine and seasonal H1N1) would be useful
-----------------------------------------
Sollte der Virus sich verbreiten muß ein NEUER Impfstoff dafür entwickelt werden, dann sind in der Zwischzeit Relanza oder Tamiflu die letzte Bastion die Krankeit zu behandeln !
Aktientechnisch gilt dann eher der Blick auf die antiviralen Grippemittel,
bzw. den Aktien Biota (Relenza + Laninamivir), Glaxo , Roche, Gilead (Tamiflu), Biocryst (Peramivir)
gruß
massel
ENDLICH kommt der Laden mal zurück. Bei NVAX gabs ja das letzte halbe Jahr nur eine Richtung...
Hoffe, dass der Kurs mal etwas konsolidiert und man sich gemütlich auf die Lauer legen kann
Hoffe, dass der Kurs mal etwas konsolidiert und man sich gemütlich auf die Lauer legen kann
...hammer wies zurückging.... mal schaun
vielleicht wurde jetzt ausgeprügelt...
Chart ist noch mega intakt
vielleicht wurde jetzt ausgeprügelt...
Chart ist noch mega intakt
vielleicht heute umgekehrt erst runter und dann hoch,werden zur zeit ganz schön verprügelt,hätte man gestern mal rausgehen sollen
Trading Spotlight
Ach, die ANALsyten...
Geb ich persönlich nicht so viel drauf.
Die von einem Biosektor-Newsletter hatten doch vor ein paar Wochen
AVI "uneingeschränkt empfohlen" und ein paar Tage später ist
der Kurs dann erdrutschartig eingebrochen
Ich meinte diese News:
NEW DELHI: Ahmedabad-based Cadila pharma to become the first firm to manufacture vaccine for H1N1 in India. US-based biotechnology firm Novavax, in
which Cadila has equity stake, has developed vaccine for the treatment of H1N1 virus. Two shots of vaccine within 3-week period will immunize person against flu.
Cadila says clinical trials on animals have been completed and tests on humans will begin in Ahmedabad shortly.
Cadila is approaching government for fast track clearance and hopes to manufacture vaccine by 2009 end. Initialy, it plans capacity of 2 million vaccines per month.
http://timesofindia.indiatimes.com/news/india/Cadila-Pharma-…
Was mich an der von Dir zitierten Meldung etwas stutzig macht,
ist dass die Tests vor allem an älteren Personen über 65 gemacht
werden sollen...
Warum das denn ??
Die wollen doch wohl hoffentlich einen Impfstoff produzieren, der
für alle Altersgruppen eingesetzt werden kann.
Die Meldung ist allerdings von Juli, vielleicht hat sich da ja
noch was geändert.
Zudem könnte sich auch was im Zeitablauf und der Produktionsmenge ändern.
Bisher ja Ende des Jahres und 2 Millionen Dosen pro Monat.
Der Bedarf dürfte aber weiter steigen, so dass ich mir vorstellen
kann, dass alles deutlich schneller gehen könnte und in grösseren
Stückzahlen.
In der jetzigen Situation wären auch Fast Track-Approvals in
anderen Ländern denkbar, immer vorausgesetzt der Impfstoff
besteht die abschliessenden Tests in Indien und diese
entsprechen internationalem Standard.
Wenn dem so ist, kann ich mir vorstellen, dass hier noch einiges
möglich ist, denn so extrem explodiert wie andere Werte ist
Nvax noch nicht.
Gruß
Eric
Geb ich persönlich nicht so viel drauf.
Die von einem Biosektor-Newsletter hatten doch vor ein paar Wochen
AVI "uneingeschränkt empfohlen" und ein paar Tage später ist
der Kurs dann erdrutschartig eingebrochen
Ich meinte diese News:
NEW DELHI: Ahmedabad-based Cadila pharma to become the first firm to manufacture vaccine for H1N1 in India. US-based biotechnology firm Novavax, in
which Cadila has equity stake, has developed vaccine for the treatment of H1N1 virus. Two shots of vaccine within 3-week period will immunize person against flu.
Cadila says clinical trials on animals have been completed and tests on humans will begin in Ahmedabad shortly.
Cadila is approaching government for fast track clearance and hopes to manufacture vaccine by 2009 end. Initialy, it plans capacity of 2 million vaccines per month.
http://timesofindia.indiatimes.com/news/india/Cadila-Pharma-…
Was mich an der von Dir zitierten Meldung etwas stutzig macht,
ist dass die Tests vor allem an älteren Personen über 65 gemacht
werden sollen...
Warum das denn ??
Die wollen doch wohl hoffentlich einen Impfstoff produzieren, der
für alle Altersgruppen eingesetzt werden kann.
Die Meldung ist allerdings von Juli, vielleicht hat sich da ja
noch was geändert.
Zudem könnte sich auch was im Zeitablauf und der Produktionsmenge ändern.
Bisher ja Ende des Jahres und 2 Millionen Dosen pro Monat.
Der Bedarf dürfte aber weiter steigen, so dass ich mir vorstellen
kann, dass alles deutlich schneller gehen könnte und in grösseren
Stückzahlen.
In der jetzigen Situation wären auch Fast Track-Approvals in
anderen Ländern denkbar, immer vorausgesetzt der Impfstoff
besteht die abschliessenden Tests in Indien und diese
entsprechen internationalem Standard.
Wenn dem so ist, kann ich mir vorstellen, dass hier noch einiges
möglich ist, denn so extrem explodiert wie andere Werte ist
Nvax noch nicht.
Gruß
Eric
Antwort auf Beitrag Nr.: 37.902.921 von 360 am 02.09.09 15:34:34es gibt nichts schlimmeres als Analysten
kein Wunder fällt NVAX:
NEW YORK (AP) -- Oppenheimer & Co. analyst Dr. Brian Abrahams downgraded shares of biotechnology company Novavax Inc. Wednesday after the biotechnology company's stock climbed past his $6 price target.
"Progress with both seasonal and pandemic vaccines, as well as the potential application of Novavax's technology against H1N1 (swine) flu, has led to substantial upside for shares over the past several months," he wrote in a note to investors.
Abrahams downgraded shares to "Perform" from "Outperform." Shares closed at $6.65 Tuesday. They have more than tripled in value since June.
The analyst said positive midstage study data on the company's 3-in-1 flu vaccine generally validates the company's technology. The vaccine is aimed at swine flu and two other strains of influenza.
"We expect Novavax will remain in high focus, particularly entering the flu season, when there are likely to be numerous pandemic flu headlines," he said.
NEW YORK (AP) -- Oppenheimer & Co. analyst Dr. Brian Abrahams downgraded shares of biotechnology company Novavax Inc. Wednesday after the biotechnology company's stock climbed past his $6 price target.
"Progress with both seasonal and pandemic vaccines, as well as the potential application of Novavax's technology against H1N1 (swine) flu, has led to substantial upside for shares over the past several months," he wrote in a note to investors.
Abrahams downgraded shares to "Perform" from "Outperform." Shares closed at $6.65 Tuesday. They have more than tripled in value since June.
The analyst said positive midstage study data on the company's 3-in-1 flu vaccine generally validates the company's technology. The vaccine is aimed at swine flu and two other strains of influenza.
"We expect Novavax will remain in high focus, particularly entering the flu season, when there are likely to be numerous pandemic flu headlines," he said.
Antwort auf Beitrag Nr.: 37.902.480 von eric949 am 02.09.09 14:57:55meinst Du dies?
Z.B. folgendes
http://economictimes.indiatimes.com/News/News-By-Industry/He…
Interessant scheint mir dabei:
“We have already carried out significant trials on humans under the scrutiny of the USFDA and the product looks safe,” Mr Singhvi claimed.
Mr Lambert said there is a huge potential for the vaccine as the flu virus keeps mutating. With the increase in instances of flu virus mutation, governments all over the world have to keep themselves prepared to deal with any kind of new flu viruses or outbreak of a flu pandemic.
Z.B. folgendes
http://economictimes.indiatimes.com/News/News-By-Industry/He…
Interessant scheint mir dabei:
“We have already carried out significant trials on humans under the scrutiny of the USFDA and the product looks safe,” Mr Singhvi claimed.
Mr Lambert said there is a huge potential for the vaccine as the flu virus keeps mutating. With the increase in instances of flu virus mutation, governments all over the world have to keep themselves prepared to deal with any kind of new flu viruses or outbreak of a flu pandemic.
Ist natürlich ne ganz nette Meldung mit den geplanten Human Trials
im 4.Quartal - aber was meiner Meinung nach derzeit wichtiger ist
sind die ABSCHLIESSENDEN Human Trials und die darauf folgende
Produktion in Indien.
Wenn ich mich recht erinnere, sind die Human Trials in Indien
doch schon am Laufen, oder ?
Da gab´s glaube ich mal ne News zu, in der auch erwähnt wurde, wann die Produktion in Indien starten soll.
Vielleicht kann die jemand noch mal reinstellen, wäre super !
Gruß
Eric
im 4.Quartal - aber was meiner Meinung nach derzeit wichtiger ist
sind die ABSCHLIESSENDEN Human Trials und die darauf folgende
Produktion in Indien.
Wenn ich mich recht erinnere, sind die Human Trials in Indien
doch schon am Laufen, oder ?
Da gab´s glaube ich mal ne News zu, in der auch erwähnt wurde, wann die Produktion in Indien starten soll.
Vielleicht kann die jemand noch mal reinstellen, wäre super !
Gruß
Eric
Durchsuchen
23.05.24 · wallstreetONLINE Redaktion · Pfizer |
Shortseller bluten: Novavax: Aktie steigt um weitere 50 Prozent – Sanofi-Deal leitet Turnaround ein! 14.05.24 · wallstreetONLINE Redaktion · Sanofi |
10.05.24 · dpa-AFX · McDonald's |
10.05.24 · dpa-AFX · 3M |
10.05.24 · dpa-AFX · Enel |
10.05.24 · dpa-AFX · 3M |
10.05.24 · dpa-AFX · Sanofi |
